Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal The Indonesian Biomedical Journal
Andi Wijaya
Prodia Clinical Laboratory, Jl. Kramat Raya No. 150, Jakarta, 10430
Biochemistry, Genetics & Molecular Biology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Roles of Mesenchymal Stem Cell-derived Extracellular Vesicles in Cancer: Development and Target Therapy Anna Meiliana; Nurrani Mustika Dewi; Andi Wijaya
The Indonesian Biomedical Journal Vol 17, No 1 (2025)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v17i1.3408

Abstract

Extracellular vesicles (EVs) are membrane structures that enclose proteins, lipids, RNAs, metabolites, growth factors, and cytokines. EVs derived from mesenchymal stem cells (MSCs) can either stimulate or inhibit tumor growth in various malignancies through paracrine signaling. Tumor-associated MSCs (TA-MSCs), often described as "wounds that never heal," actively participate in the development, propagation, and metastasis of tumors, impacting the immunological state of the tumor microenvironment. For instance, TA-MSCs can alter immune cell recruitment and cytokine production, leading to a pro-tumorigenic environment. Consequently, both the tumor and its microenvironment undergo functional alterations, the cargo of exosomes is modified, and an abnormal tumor-associated MSC phenotype is acquired. MSC-EVs contain exosome microRNA with both tumor-inhibitory and tumor-supportive effects. For example, MSC-EVs have been shown to deliver tumor-suppressive microRNAs that inhibit cancer cell proliferation and induce apoptosis. This review outlines the criteria for the modification, isolation, and characterization of exosomes, as well as their application in cancer, providing insights for clinical use. By understanding these mechanisms, we can better harness MSC-EVs for therapeutic purposes.Keywords: mesenchymal stem cell, extracellular vesicle, exosome, cancer therapy, drug delivery
Resveratrol: The Multifaceted Roles and Mechanisms of Polyphenol to Improve Longevity, Immunomodulation, and Age-related Diseases Anna Meiliana; Nurrani Mustika Dewi; Andi Wijaya
The Indonesian Biomedical Journal Vol 17, No 2 (2025)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v17i2.3486

Abstract

High in polyphenols diet has been known to protect human against chronic metabolic diseases including cancer, diabetes, neurological and cardiovascular disorders. Resveratrol (RSV) is a natural polyphenol that presents in fruits, vegetables, and nuts. The polyphenols content of RSV possesses anti-inflammatory, antioxidant, immunomodulatory, and anticancer properties by influencing the nuclear factor-kappaB (NF-κB), p53, adenosine monophosphate-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathways, enzymatic antioxidants expressions, and the levels of microRNAs. Therefore, this review article will focus on the potential of RSV in improving aging and metabolic diseases, which mostly induced by low-chronic inflammation and oxidative stress. RSV is also known as calorie restriction (CR)-mimetics to activate sirtuins family which improve mitochondrial function, repair DNA and genomic stability and reduce inflammation thus become a promising substance to extend health span and longevity. RSV can be useful as a supplement to prevent aging-related diseases, with a dose range between 250–1,000 mg depending on the intended health benefit and individual factors. More clinical data is needed to determine the impact of RSV metabolites and the relationship between dose, concentration, and effect, particularly in the context of chronic illness.KEYWORDS: mesenchymal stem cell, extracellular vesicle, exosome, cancer therapy, drug delivery
Co-Authors Anna Meiliana Nurrani Mustika Dewi